Barr Pharmaceuticals
Aug 07, 08

NEW STORY
07:25 ET Barr Reports Second Quarter 2008 GAAP Earnings of $0.52 Per Share; Adjusted Earnings of $0.64 Per Share

  
Jul 31, 08

11:57 ET Barr Confirms Patent Challenge of Xyzal(R), 5mg Tablets

  
Jul 29, 08

09:10 ET Barr Confirms Patent Challenge of Sensipar(R) Tablets, 30mg, 60mg and 90mg

  
Jul 24, 08

14:45 ET Barr Confirms Patent Challenge of Fentora(R) Tablets

  
Jul 18, 08

07:00 ET Teva to Acquire Barr

  
Jul 03, 08

10:10 ET Barr Will Host an Earnings Conference Call on August 7, 2008 to Discuss the Results for the Second Quarter of Calendar 2008

  
Jun 26, 08

17:20 ET Barr Announces Favorable Ruling in Mirapex(R) Patent Challenge

  
Jun 24, 08

02:00 ET Barr and Bayer Sign Supply and Licensing Agreements for Launch of Generic Yasmin(R) and Yaz(R) Oral Contraceptives

  
Jun 10, 08

15:34 ET Barr Confirms Patent Challenge of Prevacid(R) SoluTab(TM) Delayed-Release Orally Disintegrating Tablets, 15mg and 30mg

  
May 27, 08

16:04 ET Barr Confirms Patent Challenge of Entocort(R), 3mg Enteric Coated Capsules

  
May 09, 08

15:35 ET Barr Announces Approval of Generic Yasmin(R)

  
May 08, 08

07:26 ET Barr Reports First Quarter 2008 GAAP Earnings of $0.21 Per Share; Adjusted Earnings of $0.57 Per Share

  
Apr 07, 08

11:26 ET Barr Will Host An Earnings Conference Call on May 8, 2008 to Discuss the Results for the First Quarter of Calendar 2008

  
Mar 28, 08

08:58 ET Barr Pharmaceuticals, Inc. Executive Bios

  
08:57 ET Barr Announces Reorganization of Senior Management, Business Functions

  
Mar 18, 08

10:00 ET Barr's PLIVA Subsidiary to Terminate GDR Deposit Agreement and Delist From London Stock Exchange

  
Mar 12, 08

15:45 ET Barr Receives Approval for Generic Taxol(R) Injection USP, 6mg/mL

  
Mar 05, 08

08:57 ET Barr Subsidiary Sues Watson for SEASONIQUE(R) Patent Infringement

  
Mar 03, 08

16:53 ET Barr Announces Favorable Ruling in Yasmin(R) Patent Challenge

  
Feb 28, 08

07:30 ET Barr Reports GAAP Earnings of $1.18 Per Share for 2007 and $0.30 Per Share for the Fourth Quarter; Adjusted Earnings Were $3.16 Per Share for 2007 and $0.79 Per Share for the Fourth Quarter

  
Feb 26, 08

08:34 ET Barr Confirms Patent Challenge of Avodart(R) Soft Gelatin Capsules, 0.5mg

  
Feb 25, 08

10:06 ET Duramed's Lo SEASONIQUE(R) NDA Accepted for Filing by FDA

  
Feb 21, 08

13:23 ET AmniScreen(TM) Amniotic Fluid Detection Device is Now Available

  
Feb 19, 08

12:56 ET Barr Receives Final Approval for Generic Mirapex(R) Tablets, 0.125mg, 0.25mg, 0.5mg, 1mg & 1.5mg

  
Feb 06, 08

09:07 ET Barr Launches Generic Fosamax(R) Tablets, 70 mg

  
Jan 23, 08

13:43 ET SEASONIQUE(R) Patent Issues

  
Jan 22, 08

13:37 ET Barr and Ortho Women's Health & Urology in Discussions to Settle ORTHO TRI-CYCLEN(R) LO Patent Litigation

  
Jan 18, 08

12:16 ET Barr Will Host Calendar 2007 and Fourth Quarter Earnings Conference Call on February 28, 2008

  
Jan 11, 08

13:02 ET Barr Confirms Patent Challenge of Namenda(R) Tablets, 5mg & 10mg

  
Jan 09, 08

10:23 ET Barr Confirms Patent Challenge of Eloxatin(R) Injectable, 5mg/mL

  
Jan 02, 08

10:06 ET Barr Confirms Patent Challenge of Argatroban(R)

  
10:04 ET Barr Receives Approval for Generic KYTRIL(R) Tablets, 1mg (Base)

  
Dec 14, 07

09:00 ET Barr Subsidiary Sues Watson and Sandoz for SEASONALE(R) Patent Infringement

  
Nov 29, 07

14:44 ET Barr Receives Approval for Generic Combunox(R) Tablets, 5mg/400mg

  
Nov 20, 07

10:30 ET Barr Confirms Patent Challenge of Focalin(R) XR

  
Nov 08, 07

07:27 ET Barr Reports Third Quarter 2007 GAAP Earnings of $0.36 Per Share; Adjusted Earnings of $0.75 Per Share

  
Nov 02, 07

11:27 ET Barr Confirms Patent Challenge of Ritalin(R) LA

  
Oct 30, 07

09:26 ET Barr Receives Tentative Approval for a Generic Version of Mirapex(R) Tablets, 0.125mg, 0.25mg, 0.5mg, 1mg and 1.5mg

  
Oct 26, 07

15:59 ET Barr's Generic Version of Estrostep(R) Fe Tablets Approved

  
Oct 25, 07

10:52 ET Barr Confirms Filing an Application With a Paragraph IV Certification for Patanol(R) Ophthalmic Solution, 0.1%

  
Oct 15, 07

08:30 ET Barr and Par Settle Diazepam Rectal Gel Patent Challenge with Valeant

  
Oct 05, 07

09:20 ET Barr Will Host Calendar 2007 Third Quarter Earnings Conference Call on November 8, 2007

  
Oct 02, 07

16:13 ET Duramed Launches New Indication for ENJUVIA(TM) (Synthetic Conjugated Estrogens, B) at North American Menopause Society Annual Meeting

  
Sep 25, 07

11:18 ET Barr Confirms Patent Challenge of UROXATRAL(R)

  
08:49 ET Patent and Trademark Office Reissues SEASONALE(R) '032 Patent

  
Aug 28, 07

09:06 ET Barr's Portia(R) Generic Oral Contraceptive Approved and Launched in Canada

  
Aug 15, 07

12:05 ET Barr Confirms Filing an Application With a Paragraph IV Certification for Femcon(R) FE Chewable Oral Contraceptive Product

  
Aug 08, 07

07:15 ET Barr Reports Second Quarter 2007 GAAP Earnings of $0.41 Per Share; Adjusted Earnings of $0.84 Per Share

  
Aug 02, 07

07:00 ET Barr Announces Departure of President and COO; CEO Downey to Assume Responsibilities

  
Jul 24, 07

09:48 ET Barr Confirms Patent Challenge of TEMODAR(R)

  
Jul 16, 07

10:04 ET Barr Confirms Patent Challenge of Xopenex(R) Inhalation Solution, 0.31mg/3mL, 0.63mg/3mL and 1.25mg/3mL

  
Jul 12, 07

12:42 ET Barr Confirms Patent Challenge of Aggrenox(R)

  
Jul 11, 07

12:40 ET Barr Will Host Calendar 2007 Second Quarter Earnings Conference Call on August 8, 2007

  
Jul 09, 07

09:07 ET Barr Announces Approval of Generic Dostinex(R)

  
Jul 05, 07

10:02 ET Duramed Announces Canadian Approval of SEASONALE(R) Extended-Cycle Oral Contraceptive

  
Jul 02, 07

14:09 ET Barr to Market Generic LAMISIL(R)

  
Jun 26, 07

10:23 ET Barr Announces Tentative Approval for a Generic Version of Effexor(R) Tablets, 25mg, 37.5mg, 50mg, 75mg and 100mg

  
Jun 25, 07

14:05 ET U.S. Supreme Court Denies Review of Tamoxifen Citrate Antitrust Lawsuits

  
Jun 22, 07

09:29 ET Barr Receives Approval for Generic VESANOID(R) Capsules, 10 mg

  
Jun 11, 07

10:08 ET Barr Announces Withdrawal of ZYPREXA(R) Zydis(R) Patent Litigation

  
Jun 05, 07

08:37 ET Barr Announces Tentative Approval for a Generic Version of Risperdal(R) Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg

  
Jun 04, 07

12:31 ET Barr and Eli Lilly Voluntarily Dismiss Patent Litigation on Prozac(R) Weekly(TM)

  
Jun 01, 07

09:15 ET Barr Confirms Decision in Azithromycin Inventorship Suit

  
May 11, 07

11:25 ET Barr Receives Tentative Approval for a Generic Version of Razadyne(R) Tablets, 4mg, 8mg and 12mg

  
May 09, 07

07:12 ET Barr Reports First Quarter 2007 GAAP Earnings of $0.11 Per Share; Adjusted Earnings of $0.78 Per Share

  
May 02, 07

11:31 ET Barr Receives Approval for Generic Nimotop(R) Capsules, 30 mg

  
Apr 30, 07

10:30 ET Duramed's ENJUVIA(TM) (Synthetic Conjugated Estrogens, B) Tablets Receives Two New FDA Approvals

  
Apr 17, 07

12:49 ET Barr Will Host An Earnings Conference Call on May 9, 2007 to Discuss the Results for the First Quarter of Calendar 2007

  
Apr 09, 07

09:42 ET Patent and Trademark Office Issues Notice of Allowance on Barr's Reissue Application for SEASONALE(R) '032 Patent

  
Apr 06, 07

11:39 ET Barr Confirms Patent Challenge of Ambien CR(R)

  
Mar 20, 07

12:43 ET Barr Confirms Filing an Application with a Paragraph IV Certification for ABILIFY(R) Tablets

  
Feb 28, 07

07:30 ET Barr Reports GAAP Loss For Three and Six Months Ended December 31, 2006 of $3.67 Per Share and $3.18 Per Share; Adjusted Earnings For Three and Six Months Were $0.83 Per Share and $1.70 Per Share

  
Feb 06, 07

15:44 ET Barr's Subsidiary PLIVA Receives Final Approval for Generic ZOLOFT(R) Tablets, 25 mg, 50 mg and 100 mg

  
Jan 30, 07

14:59 ET Barr Launches Generic PROSCAR(R) Tablets, 5 mg

  
Jan 23, 07

15:34 ET Barr Confirms Generic Thalomid(R) Suit Filed

  
09:28 ET Barr's Subsidiary PLIVA Receives Approval for Generic ZITHROMAX(R) IV, 500 mg Vial

  
Jan 19, 07

12:33 ET Barr Will Host an Earnings Conference Call on February 28, 2007 to Discuss the Results for the Quarter and Six Months Ended December 31, 2006

  
08:53 ET Barr Launches Generic METAGLIP(TM) Tablets, 2.5/250 mg, 2.5/500 mg and 5/500 mg

  
Jan 18, 07

11:53 ET Barr Receives Tentative Approval for Generic KYTRIL(R) Tablets, 1mg (Base)

  
Dec 26, 06

11:48 ET Barr Confirms Generic Thalomid(R) Capsule, 50 mg and 100 mg Application

  
11:19 ET Barr's Subsidiary PLIVA Launches Ondansetron 4 mg and 8 mg Orally Disintegrating Tablets

  
Dec 13, 06

12:11 ET Barr Confirms Generic Thalomid(R) Capsule Application

  
Nov 28, 06

03:30 ET Barr's Subsidiary PLIVA Receives Approval for Pravastatin Tablets 10mg, 20mg, and 40mg and Tentative Approval for 80mg

  
Nov 09, 06

14:45 ET Barr Receives Tentative Approval for a Generic Version of ZYPREXA(R) Zydis(R) Tablets, 5mg, 10mg, 15mg and 20mg

  
Nov 08, 06

07:14 ET Barr Reports GAAP Earnings of $0.49 Per Share for Quarter Ended September 30, 2006; Adjusted Earnings Were $0.78 Per Share

  
Nov 06, 06

08:36 ET Barr Launches Plan B(R) OTC/Rx Dual-Label Product; Awarded 3 Years New Product Exclusivity

  
Oct 31, 06

08:40 ET PLIVA Announces Changes in Management and Supervisory Boards

  
Oct 24, 06

08:36 ET Barr Finalizes Acquisition of PLIVA d.d.

  
Oct 20, 06

12:36 ET Barr Says FTC Has Cleared Acquisition of PLIVA d.d.

  
02:00 ET Barr Acquires PLIVA d.d. Following Official Closing of Tender Offer Process

  
Oct 12, 06

07:31 ET Barr's Formal Tender Offer Period for PLIVA d.d. Officially Closes

  
Oct 10, 06

10:14 ET Barr Will Host Earnings Conference Call on November 8, 2006 to Discuss the Results for the Quarter Ended September 30, 2006

  
Sep 28, 06

08:03 ET Barr Cleared to Launch ADDERALL(R) IR

  
Sep 27, 06

08:13 ET Barr Launches Generic ACTIQ(R) Cancer Pain Management Product

  
Sep 26, 06

18:21 ET Barr Confirms Patent Challenge of Oxandrin(R) Tablets, 2.5 mg and 10 mg

  
11:17 ET Barr Announces Warner Chilcott Waives Exclusive License for OVCON(R) 35

  
Sep 18, 06

10:52 ET U.S. Court of Appeals Denies Rehearing Request in Dismissal of Tamoxifen Citrate Antitrust Lawsuits

  
Sep 11, 06

07:48 ET Barr's Amended Tender Offer for PLIVA d.d. Approved for Publication by HANFA

  
Sep 08, 06

09:37 ET Barr Files an Amended Tender Offer for PLIVA d.d. With HANFA

  
Sep 07, 06

10:00 ET Barr Launches a Generic Version of its SEASONALE(R) Extended-Cycle Oral Contraceptive

  
Aug 31, 06

11:25 ET Barr Evaluating Actavis Group's Competing Bid for PLIVA d.d.

  
Aug 24, 06

09:00 ET FDA Grants OTC Status to Barr's Plan B(R) Emergency Contraceptive

  
Aug 18, 06

02:30 ET Barr Initiates Formal Tender Offer for PLIVA d.d.

  
Aug 15, 06

07:18 ET Barr Reports GAAP Earnings of $3.12 Per Share for Fiscal 2006 and GAAP Earnings of $0.76 Per Share for Fourth Quarter on Strong Revenue Growth

  
Aug 14, 06

20:45 ET Barr and Shire Sign Three Agreements: A Product Acquisition Agreement for ADDERALL(R); A Product Development Agreement; and A Settlement and License Agreement for ADDERALL XR(R)

  
Aug 10, 06

09:25 ET Barr Offer for PLIVA d.d. Approved for Publication by HANFA

  
Aug 02, 06

13:19 ET Barr Will Host Fourth Quarter and Full Year Fiscal 2006 Earnings Conference Call on August 15, 2006

  
Aug 01, 06

08:41 ET Barr Receives Approval for Generic XANAX XR(R) Tablets

  
Jul 28, 06

09:50 ET Barr Files Formal Tender Offer for PLIVA d.d. With HANFA

  
Jul 24, 06

03:30 ET Barr Prepared to Satisfy FTC Requirements for Potential Acquisition of PLIVA d.d.

  
Jul 14, 06

09:05 ET Duramed and Common Sense Sign Agreement to Develop and Market AL-SENSE(R) Amniotic Fluid Detection Device

  
Jul 07, 06

03:30 ET Barr Files for FTC, German Regulatory Approval of Proposed PLIVA Acquisition

  
Jul 06, 06

15:04 ET Barr Confirms Patent Challenge of Razadyne(R) ER Capsules

  
Jul 03, 06

03:30 ET Barr Board Reaffirms Commitment to HANFA Takeover Process

  
Jun 30, 06

03:00 ET Barr Increases Offer for PLIVA d.d. to $2.3 Billion in Cash, or HRK 743 Per Share

  
Jun 27, 06

02:32 ET Fact Sheet of Barr Pharmaceuticals, Inc. and PLIVA d.d.

  
02:31 ET Barr Will Host Conference Call to Discuss the Bid for PLIVA d.d.

  
02:30 ET Barr Announces Offer of $2.2 Billion for PLIVA d.d.

  
Jun 12, 06

08:02 ET Barr Confirms Settlement With Sandoz Regarding Warfarin Sodium

  
May 25, 06

15:26 ET FDA Approves Duramed's SEASONIQUE(TM) Extended-Cycle Oral Contraceptive Company's Second Proprietary Extended-Cycle OC to be Available in July

  
May 12, 06

13:40 ET Barr Receives Approval for Isotretinoin Capsules USP, 30 mg

  
08:01 ET Barr Will Host Conference Call to Discuss the Non-Final Rejection Notice From Patent and Trademark Office on Duramed's Reissue Application for SEASONALE(R)

  
08:00 ET Barr Confirms Non-Final Rejection Notice From Patent and Trademark Office on Duramed's Reissue Application for SEASONALE(R) '032 Patent

  
May 11, 06

10:10 ET Barr Challenging Patents Protecting Prozac(R) Weekly(TM)

  
May 08, 06

07:30 ET Duramed's ENJUVIA(TM) (Synthetic Conjugated Estrogens, B) Now Available in Pharmacies Nationwide

  
May 04, 06

07:30 ET Barr Confirms Patent Challenge of NASACORT(R) AQ Nasal Spray

  
07:30 ET Barr Reports Third Quarter Fiscal 2006 GAAP Earnings of $0.70 Per Share; Adjusted Earnings of $0.75 Per Share

  
Apr 06, 06

15:03 ET Barr Will Host Fiscal 2006 Third Quarter Earnings Conference Call on May 4, 2006

  
08:54 ET Barr's Duramed Withdraws NDA for Lo SEASONALE(R) Extended-Cycle Oral Contraceptive

  
Mar 17, 06

08:34 ET Barr Confirms that Additional Clinical Data Is Not Required for Approval of Duramed's SEASONIQUE(TM) Extended-Cycle Oral Contraceptive

  
Feb 15, 06

13:53 ET Federal Court Affirms Barr Summary Judgment in DDAVP(R) Patent Challenge

  
Feb 07, 06

07:32 ET Barr Reports Second Quarter Fiscal 2006 GAAP Earnings of $0.88 Per Share; Adjusted Earnings of $0.85 Per Share

  
Feb 01, 06

19:33 ET Barr Announces Agreements with Cephalon, Inc. Regarding Settlement of ACTIQ(R) and PROVIGIL(R) Patent Litigations

  
Jan 27, 06

15:12 ET Barr Says Court Denies Preliminary Injunction to Halt Generic Allegra(R) Sales

  
Jan 20, 06

11:23 ET Barr Will Host Fiscal 2006 Second Quarter Earnings Conference Call on February 7, 2006

  
Jan 17, 06

08:49 ET Barr's Duramed Pharmaceuticals Named Title Sponsor of the FUTURES(R) Golf Tour

  
Jan 10, 06

12:18 ET Barr Names G. Frederick Wilkinson President and COO of Duramed Pharmaceuticals, Inc.

  
Dec 23, 05

09:00 ET Barr Receives Approval for Zonisamide Capsules, 25 mg, 50 mg & 100 mg

  
Dec 19, 05

12:15 ET Barr Pharmaceuticals Announces Management Change

  
Dec 13, 05

17:31 ET Barr's Downey Files to Exercise Options for Common Shares

  
Dec 02, 05

02:30 ET Barr, Organon and Savient Finalize Mircette(R) Settlement and Acquisition

  
Nov 10, 05

08:26 ET Duramed Completes Acquisition of FEI Women's Health and ParaGard(R) IUD Product

  
Nov 07, 05

18:04 ET Barr Confirms FTC Lawsuit Related to Generic Ovcon-35(R) License

  
Nov 03, 05

14:00 ET U.S. Court of Appeals Affirms Dismissal of Tamoxifen Antitrust Lawsuits

  
12:47 ET Barr Announces Extension of Stock Repurchase Program

  
Nov 01, 05

07:33 ET Barr Reports First Quarter Fiscal 2006 Earnings of $0.78 Per Share

  
Oct 26, 05

16:48 ET Duramed and Paladin Sign SEASONALE(R) Product Canadian License and Distribution Agreement

  
Oct 25, 05

11:39 ET Barr Will Host Fiscal 2006 First Quarter Earnings Conference Call on November 1, 2005

  
Oct 18, 05

07:31 ET Barr Will Host Conference Call to Discuss Duramed's Acquisition of FEI Women's Health and Its ParaGard(R) IUD Product

  
07:31 ET Duramed to Acquire FEI Women's Health and Its ParaGard(R) IUD Product

  
Oct 17, 05

09:16 ET Barr Confirms Patent Challenge of Risperdal(R) M-Tab(R)

  
Sep 28, 05

08:30 ET Barr Confirms Patent Challenge of Mirapex(R)

  
Sep 21, 05

11:07 ET Barr Confirms That Aventis and Albany Molecular Research, Inc. Are Seeking a Preliminary Injunction on Allegra(R) Tablets

  
Sep 14, 05

08:35 ET Barr Receives Approval for Leflunomide Tablets, 10 mg & 20 mg

  
Sep 08, 05

07:32 ET Barr Reports GAAP Earnings of $2.03 Per Share for Fiscal 2005 and GAAP Earnings of $0.40 Per Share for Fourth Quarter

  
07:32 ET Barr, Organon and Savient Announce Letter of Intent Regarding Mircette(R)

  
Sep 06, 05

08:06 ET Teva and Barr Announce Launch of Generic Allegra(R) Tablets by Teva Under Agreement With Barr

  
Sep 01, 05

08:27 ET Barr Receives Approval for Allegra(R) Tablets

  
Aug 26, 05

16:00 ET FDA Defers Decision on Plan B Over-the-Counter Application

  
Aug 18, 05

08:53 ET Barr Receives Approvable Letter for Duramed's SEASONIQUE(TM) Extended-Cycle Oral Contraceptive

  
Aug 15, 05

09:41 ET Barr Will Host Fiscal 2005 Fourth Quarter and Full Year Earnings Conference Call on September 8, 2005

  
Aug 11, 05

08:35 ET Barr Receives Approval for Clonazepam Orally Disintegrating Tablets, 0.125 mg, 0.25 mg, 0.5 mg, 1 mg & 2 mg

  
Jul 14, 05

09:13 ET Barr Receives Approval For Allegra(R) Capsules

  
Jul 05, 05

08:58 ET Barr Receives Approval for DDAVP(R) Tablets, 0.1 mg & 0.2 mg

  
Jun 17, 05

11:40 ET Barr Applauds New Hampshire Law Making Emergency Contraception More Accessible

  
Jun 15, 05

10:10 ET Barr Confirms Patent Challenge of Razadyne(R) Tablets

  
May 25, 05

08:25 ET Barr's Generic Demulen 1/35-28 Oral Contraceptive Tablets Approved

  
May 05, 05

07:30 ET Barr Reports Third Quarter Fiscal 2005 Earnings of $0.58 Per Share

  
Apr 27, 05

08:36 ET Barr Receives Final FDA Approval for Generic Niaspan(R) Extended-Release Tablets

  
Apr 26, 05

10:57 ET Barr's Receives Not Approvable Letter for Bijuva(TM) Vaginal Cream

  
Apr 20, 05

14:16 ET Plan B(R) Emergency Contraceptive Granted Non-Prescription Status in Canada

  
Apr 18, 05

14:40 ET Barr Will Host Fiscal 2005 Third Quarter Earnings Conference Call on May 5, 2005

  
13:02 ET Barr Receives Approval for Anagrelide Hydrochloride Capsules, 0.5 mg and 1 mg

  
Apr 14, 05

13:23 ET Barr Granted Final Approval for Generic Version of Allegra-D(R) 12 Hour Extended-Release Tablets

  
Apr 13, 05

07:31 ET Barr Will Host Conference Call to Discuss Agreements Related to Resolution of Patent Litigation Involving Kos' Niaspan(R) Products

  
07:31 ET Kos and Barr Announce Definitive Co-Promotion, Manufacturing, and Settlement Agreements

  
Apr 11, 05

12:27 ET Barr Eligible for Sole Exclusivity on Allegra-D(R) 12 Hour

  
Apr 01, 05

10:30 ET Barr Granted Summary Judgment on Additional Patent in Allegra(R) Patent Challenge

  
Mar 31, 05

17:05 ET Barr Says Court Rejects Ciprofloxacin Antitrust Class Action Suits

  
Mar 30, 05

11:36 ET Barr and PLIVA Sign Agreement to Develop and Market Generic Version of G-CSF in United States and Canada

  
08:31 ET Barr and Kos in Settlement Discussions Regarding Niaspan(R) Patent Litigation

  
Mar 29, 05

13:14 ET Barr Confirms Filing an Application With a Paragraph IV Certification for Yasmin(R)

  
Mar 09, 05

16:04 ET Barr Confirms Kos Is Seeking Court Order to Block Potential Launch of Generic Niaspan(R)

  
Feb 09, 05

09:19 ET Court Grants Barr Summary Judgment in DDAVP(R) Patent Challenge

  
Feb 04, 05

09:07 ET Barr Sues FDA to Obtain Sole Exclusivity on Allegra-D(R)

  
Feb 02, 05

07:30 ET Barr Reports Second Quarter Fiscal 2005 Earnings of $0.56 Per Share

  
Jan 25, 05

07:59 ET Barr Confirms Court of Appeals Decision Regarding Natural Biologics Conjugated Estrogen Raw Material

  
Jan 21, 05

18:01 ET FDA Decision on Plan B(R) OTC Status Delayed

  
Jan 14, 05

09:15 ET Barr Will Host Fiscal 2005 Second Quarter Earnings Conference Call on February 2, 2005

  
Jan 07, 05

12:30 ET Barr Receives Tentative Approval for Mirtazapine Orally Disintegrating Tablets, 45 mg

  
Dec 28, 04

08:39 ET Barr's Duramed Acquires Exclusive Rights to Nordette(R)

  
Dec 22, 04

08:38 ET Duramed's SEASONIQUE(TM) NDA Accepted for Filing by FDA

  
Dec 21, 04

08:03 ET Barr Receives FDA Approval for Enjuvia(TM) (Synthetic Conjugated Estrogens, B) 0.3 and 0.45 Mg Tablets

  
Dec 13, 04

15:15 ET Barr Receives Approval for Demeclocycline Hydrochloride Tablets USP, 150 mg & 300 mg

  
Dec 03, 04

12:01 ET Barr's Generic Version of Videx(R) EC Antiretroviral Agent Approved by FDA

  
Dec 02, 04

14:01 ET Barr Confirms Suit Initiating ZYPREXA(R) Zydis(R) Patent Challenge

  
Nov 22, 04

16:20 ET Barr's Duramed to Acquire Exclusive Rights to Prefest(R)

  
Nov 04, 04

07:04 ET Barr Reports First Quarter Fiscal 2005 Earnings of $0.49 Per Share

  
Oct 21, 04

10:39 ET Barr Completes Sales Force Integration

  
Oct 20, 04

09:14 ET Barr Will Host Fiscal 2005 First Quarter Earnings Conference Call on November 4, 2004

  
Oct 19, 04

16:08 ET Federal Appeals Court Reverses Summary Judgment Decision in Antitrust Litigation

  
Oct 18, 04

08:49 ET Barr Receives Approval for Generic Glucophage(R) XR Extended-Release Tablets, 750 mg

  
Oct 06, 04

09:43 ET Barr Receives Tentative Approval for Generic Version of Femhrt(R) Tablets

  
Sep 30, 04

08:24 ET Barr's Generic Tri-Norinyl(R)-28 Oral Contraceptive Tablets Approved

  
Sep 07, 04

09:24 ET Barr Exercises Royalty Option on SEASONALE(R) Extended-cycle Oral Contraceptive

  
Aug 31, 04

10:24 ET Barr Obtains $175 Million Credit Facility

  
Aug 27, 04

08:22 ET Barr Receives Tentative Approval for a Generic Version of Zofran ODT(R) Orally Disintegrating Tablets

  
Aug 10, 04

07:54 ET Barr Granted Rights to Generic of Cephalon's ACTIQ(R) Cancer Pain Treatments

  
Aug 05, 04

07:50 ET Barr Announces Stock Repurchase Program

  
07:48 ET Barr Reports Fiscal 2004 GAAP Earnings of $1.15 Per Share and Fourth Quarter GAAP Earnings of $0.13 Per Share

  
Jul 22, 04

11:28 ET Barr Submits Response to FDA in Support of Over-the-Counter Status for Plan B(R) Emergency Contraceptive

  
09:16 ET Barr Will Host Fiscal 2004 Fourth Quarter and Full Year Earnings Conference Call on August 5, 2004

  
Jul 19, 04

14:57 ET Eastern Virginia Medical School Submits Patent Covering SEASONALE(R) for Reissue With Patent and Trademark Office

  
Jul 02, 04

08:19 ET Barr Receives Tentative Approval for Allegra(R)-D Extended-Release Tablets

  
Jul 01, 04

08:44 ET Barr Granted Summary Judgment on Three Patents in Allegra(R) Patent Challenge

  
Jun 17, 04

08:32 ET Arbitration Panel Rules Against Barr in Contract Dispute With Solvay; Panel Divided Over Damage Award

  
May 11, 04

08:17 ET Barr Receives FDA Approval for Enjuvia(TM) (Synthetic Conjugated Estrogens, B)

  
May 06, 04

18:58 ET Barr Receives Not Approvable Letter for Over-the-Counter Emergency Contraceptive

  
Apr 28, 04

07:42 ET Barr Reports Third Quarter Fiscal 2004 Earnings of $0.33 Per Share Driven by 87% Increase in Revenue

  
Apr 27, 04

16:47 ET Barr Announces Agreement with Galen Resolving Outstanding Patent Challenges on Estrostep(R) and femhrt(R)

  
Apr 23, 04

08:30 ET Barr's Generic Ovcon-35(R) Tablets Approved

  
Apr 14, 04

08:42 ET Barr Will Host Third Quarter Fiscal 2004 Earnings Conference Call on April 28, 2004

  
Apr 05, 04

08:00 ET Barr Acquires Rights to Urinary Incontinence Transvaginal Ring Product From Schering AG, Germany

  
Mar 25, 04

02:00 ET Barr and Galen Announce Agreements for Duramed to Acquire Exclusive Rights to Galen's Loestrin(R) Oral Contraceptive Products

  
Mar 16, 04

08:05 ET Barr Pharmaceuticals Board Announces Stock Split Distribution

  
Mar 08, 04

08:00 ET Webcast Alert: Barr Pharmaceuticals, Inc. Will Webcast its Third Annual Analyst Briefing on March 10, 2004

  
Mar 01, 04

08:06 ET Webcast Alert: Barr Pharmaceuticals, Inc. Will Webcast its Third Annual Analyst Briefing on March 10, 2004

  
Feb 26, 04

09:34 ET Barr Completes Acquisition of Women's Capital Corporation and Plan B(R) Emergency Contraceptive

  
Feb 25, 04

13:02 ET Barr Receives Approval for Cyclessa Oral Contraceptive Tablets

  
Feb 20, 04

12:40 ET Barr's Downey Exercises Options for Common Shares

  
Feb 13, 04

15:31 ET Barr Says FDA Extends Plan B Emergency Contraceptive PDUFA Date

  
08:45 ET Barr Pharmaceuticals Board Announces 3-for-2 Stock Split; Fifth Stock Split in Eight Years

  
Feb 06, 04

08:48 ET Barr's Cenestin(R) 0.45 mg Tablets Approved

  
Feb 05, 04

07:27 ET Barr's Second Quarter Fiscal 2004 GAAP Earnings of $0.49 Per Share Driven by 79% Increase in Revenues

  
Jan 26, 04

13:11 ET Barr Will Host Second Quarter Fiscal 2004 Earnings Conference Call on February 5, 2004

  
Jan 09, 04

10:55 ET Barr's Tentative Approval for Metformin XR Withdrawn by FDA

  
Jan 08, 04

10:43 ET Barr Receives Tentative Approval for Modafinil Tablets, 100 mg and 200 mg

  
Jan 06, 04

12:52 ET Barr Receives Tentative Approval for Topiramate Tablets, 25 mg, 100 mg and 200 mg

  
Jan 02, 04

10:00 ET Barr Changes State of Incorporation to Delaware

  
Dec 30, 03

09:28 ET Barr Receives Approval for Mefloquine Hydrochloride Tablets

  
Dec 29, 03

13:48 ET Barr Launches Generic Version of Ortho Tri-Cyclen(R) Tablets

  
Dec 23, 03

11:45 ET Barr and Galen Receive FTC Request for Information Related to Proposed Transactions

  
Dec 19, 03

09:24 ET Barr Receives Tentative Approval for Topiramate Capsules, 15 mg and 25 mg

  
Dec 18, 03

09:06 ET Barr Receives Approval for and Launches Mirtazapine Orally Disintegrating Tablets, 15mg and 30mg

  
Dec 16, 03

17:52 ET FDA Advisory Committees Vote to Allow Over-the-Counter Sale of Emergency Contraceptive

  
Dec 04, 03

10:29 ET Barr Announces Challenge of Patents Protecting Prefest(R)

  
Dec 03, 03

07:42 ET Barr Will Host Conference Call to Discuss Asset Purchase Agreement with Endeavor Pharmaceuticals, Inc.

  
07:41 ET Barr to Acquire Assets of Endeavor Pharmaceuticals, Inc.; $35 Million Asset Purchase Agreement Signed

  
Nov 18, 03

10:30 ET Barr Begins Detailing SEASONALE(R) to Physicians and Healthcare Providers

  
Nov 06, 03

07:34 ET Barr Laboratories, Inc. Reports 41% Increase in Revenue Drives First Quarter Fiscal 2004 GAAP Earnings of $0.55 Per Share

  
Oct 31, 03

12:52 ET Barr Receives Tentative Approval for Metformin Hydrochloride Extended-Release Tablets, 500 mg

  
Oct 30, 03

08:05 ET Barr and Shire Announce Dismissal of ADDERALL(R) Trade Dress Suit

  
Oct 23, 03

11:20 ET SEASONALE(R), First and Only Extended-Cycle Oral Contraceptive, Is Now Available in Pharmacies Nationwide

  
Oct 21, 03

17:52 ET Barr Will Host First Quarter Fiscal 2004 Earnings Conference Call on November 6th

  
Oct 15, 03

08:05 ET Webcast Alert: Barr Laboratories, Inc. Invites You to Join Its 2003 Annual Meeting of Shareholders on the Web

  
Oct 09, 03

09:03 ET Barr's Receives Approval for Pyridostigmine Bromide Tablets USP, 60 mg

  
Oct 06, 03

08:26 ET Barr Initiates Challenge of Patent Protecting Ortho Tri-Cyclen(R) Lo

  
Oct 02, 03

09:08 ET Barr Signs Letter of Intent to Acquire Plan B Emergency Contraceptive

  
Sep 25, 03

08:34 ET Barr Signs Amended Agreement to Extend Distribution of Ciprofloxacin

  
Sep 18, 03

12:16 ET Barr's Generic Loestrin(R) Fe 1/20 and 1.5/30 Tablets Approved

  
Sep 15, 03

16:37 ET Barr to Review Options Following District Court Ruling on Natural Biologics' Generic Premarin(R) Raw Material

  
Sep 11, 03

02:05 ET Barr Will Host Conference Call to Discuss Letter of Intent With Galen

  
02:00 ET Barr and Galen Sign Letters of Intent for Barr to Acquire Exclusive Rights to Galen's Loestrin(R) Oral Contraceptive Product

  
Sep 05, 03

17:05 ET Barr Will Host a Conference Call to Discuss the Approval of SEASONALE(R), An Extended-Cycle Oral Contraceptive

  
17:00 ET FDA Approves Barr's SEASONALE(R), an Extended-Cycle Oral Contraceptive First and Only Extended-Cycle OC Gives Women New Choice - Four Periods a Year

  
Sep 03, 03

12:04 ET Barr Confirms Additional Suit by Shire for Adderall XR(R)

  
Aug 21, 03

15:56 ET Barr's Receives Approval for Lithium Carbonate Extended-Release Tablets USP, 450 mg

  
Aug 07, 03

07:51 ET Barr Reports Fiscal 2003 GAAP Earnings of $2.43 Per Share and Fourth Quarter GAAP Earnings of $0.53 Per Share

  
Jul 31, 03

16:08 ET Barr Will Host Fourth Quarter and Fiscal 2003 Full Year Earnings Conference Call on August 7th

  
08:33 ET Barr Laboratories Announces Agreement in Ortho Tri-Cyclen(R) Patent Litigation

  
Jul 09, 03

18:07 ET Barr Announces Voluntary Recall of 3 Lots of Nortrel(TM) 7/7/7 - 28 Day

  
Jul 03, 03

14:57 ET Barr Dedicates Adenovirus Manufacturing Facility

  
Jun 30, 03

11:01 ET Barr Files Application for an 'AB' Rated Conjugated Estrogens Product

  
07:01 ET Barr Relocates Administrative Headquarters to Bergen County, NJ

  
Jun 23, 03

09:16 ET Barr Receives Approval for Extended Phenytoin Sodium Capsules USP, 100 mg

  
Jun 16, 03

14:45 ET Barr Receives Tentative Approval for Generic Niaspan(R) 500 mg and 750 mg Extended-Release Tablets

  
Jun 10, 03

12:05 ET Barr Completes Agreements to Acquire Wyeth Products; Barr Receives License to Develop, Market Trimegestone Progestin

  
Jun 09, 03

08:55 ET Barr Announces Launch of Ciprofloxacin Products

  
Jun 03, 03

09:36 ET Barr Receives Not Approvable Letter for Cenestin(R) 0.45 mg Tablets

  
Jun 02, 03

08:28 ET Barr's Generic Loestrin(R) 21 1/20 and 1.5/30 Tablets Approved

  
May 27, 03

10:17 ET Barr Says Appeals Court Rejects Shire's Request for Preliminary Injunction In Adderall(R) Trade Dress Suit

  
May 23, 03

09:03 ET Barr Says FDA Extends PDUFA Deadline for SEASONALE(R) Extended-Cycle(TM) Oral Contraceptive Application

  
May 21, 03

08:10 ET Barr Announces Decision in Ciprofloxacin Antitrust Class Action Suits; Ruling Significantly Narrows Focus of Litigation

  
May 15, 03

15:46 ET Barr Announces Dismissal of Tamoxifen Antitrust Lawsuits

  
May 12, 03

13:13 ET Barr Receives Tentative Approval for Generic Niaspan(R) 1000 mg Extended-Release Tablets

  
May 09, 03

13:33 ET Barr Launches Generic Accutane(R) Capsules Product

  
Apr 24, 03

07:48 ET Barr Reports Third Quarter 2003 EPS of $0.66

  
Apr 15, 03

13:11 ET Barr Will Host Third Quarter Earnings Conference Call on April 24th

  
Apr 11, 03

13:35 ET Barr Receives Approval for Generic Accutane(R) Capsules

  
Apr 01, 03

16:48 ET Barr to Continue Marketing Kariva(TM) Despite Court of Appeals Decision; Barr's Patent Challenge For Mircette(R) Oral Contraceptive Remanded To District Court for Trial

  
Mar 31, 03

09:44 ET Barr Initiates Patent Challenge of Provigil(R) Tablets

  
Mar 19, 03

15:45 ET Barr Receives Approval for Generic ADDERALL(R) Tablets, 7.5 mg, 12.5 mg, 15 mg

  
Mar 18, 03

08:54 ET Barr Laboratories Board Announces Stock Split Distribution

  
Feb 25, 03

11:42 ET Barr Confirms Shire Suit Initiating Adderall XR(TM) Patent Challenge

  
Feb 21, 03

08:49 ET Barr Receives Approval for Generic Nolvadex(R) 10 mg and 20 mg Tablets

  
Feb 18, 03

16:31 ET Barr Laboratories Board Announces 3 for 2 Stock Split; Fourth Stock Split in Seven Years

  
09:55 ET Barr's CEO Downey to Begin Outpatient Therapy; Returns Home, Resumes Full-Time Business Schedule

  
Feb 13, 03

09:16 ET Barr to Relocate Executive Offices to Bergen County, NJ; Signs 12 Year Lease on Woodcliff Lake Facility; Adequate Room for Growth

  
Jan 23, 03

09:08 ET Barr Receives Approval for Generic Florinef(R) Acetate Tablets USP, 0.1 mg

  
Jan 22, 03

16:21 ET Barr Hosts Second Annual Analyst Meeting

  
Jan 21, 03

08:40 ET Barr Reports Second Quarter 2003 EPS of $0.94 - Strong Oral Contraceptive Sales Drive Results -

  
Jan 14, 03

07:50 ET Barr Increases Second Quarter Earnings Estimates

  
Jan 06, 03

08:06 ET Barr's CEO Downey Undergoing Treatment for Transverse Myelitis; Remains Active in Company Management

  
Dec 18, 02

19:28 ET Barr's Generic Ortho Tri-Cyclen(R) Receives Final FDA Approval

  
19:28 ET District Court Refuses to Allow Barr to Market its Manufactured Tamoxifen 10 mg Tablet Before February 2003

  
Dec 17, 02

11:56 ET Barr Initiates Patent Challenge of DDAVP(R) Tablets

  
Dec 02, 02

08:08 ET Barr Signs Letter of Intent to Acquire Currently Marketed Wyeth Products

  
Nov 12, 02

16:25 ET Barr Confirms Evista(R) Patent Challenge

  
Nov 07, 02

07:42 ET Barr Reports $0.92 EPS in First Quarter 2003; Strong Sales, Increased Margins Drive Results

  
Oct 30, 02

09:04 ET Barr Receives Approval For Generic Tambocor(TM) Heart Drug

  
Oct 24, 02

11:53 ET Election of Board of Directors of Barr Laboratories, Inc.

  
Oct 22, 02

08:52 ET Barr Receives Final FDA Approval for Two Oral Contraceptives; Company Will Launch Generic Versions of NOR-QD(R) and Ortho-Micronor(R)

  
Oct 17, 02

08:07 ET Barr Laboratories, Inc. Invites You to Join Its 2002 Annual Meeting of Shareholders on the Web

  
07:45 ET Barr Laboratories, Inc. Invites You to Join Its 2002 Annual Meeting of Shareholders on the Web

  
Sep 25, 02

12:55 ET Barr's Generic Ortho-Cyclen(R) Tablets Approved; Company to Market Oral Contraceptive Under Sprintec(TM) Trademark

  
Sep 23, 02

00:01 ET Barr to Challenge FDA Opinion that Delays Launch of Its Manufactured Tamoxifen 10 mg Tablet

  
Sep 17, 02

13:00 ET Barr's SEASONALE(R) NDA Accepted for Filing by FDA

  
Sep 04, 02

09:32 ET Barr's Nortel(TM) 7/7/7 Oral Contraceptive Receives Final Approval; Company Plans to Launch Generic Product in January 2003, Nine Months Prior To Patent Expiry

  
Aug 29, 02

09:18 ET District Court Denies Shire's Motion for Preliminary Injunction in Adderall(R) Trade Dress Infringement Suit

  
Aug 19, 02

11:54 ET Barr Challenging Patents Protecting Niaspan(R) 500 and 750 mg Extended Release Tablets

  
Aug 14, 02

08:10 ET Barr Reports Fiscal 2002 Earnings of $4.63 Per Share and Fourth Quarter Earnings of $0.98 Per Share Earnings for the Year Reflect Merger Charges and Other Items

  
08:00 ET Webcast Alert: Barr Laboratories, Inc. Announces Fourth Quarter/Fiscal 2002 Year End Webcast

  
08:00 ET Webcast Alert: Barr Laboratories, Inc. Announces Fourth Quarter/Fiscal 2002 Year End Webcast

  
Aug 07, 02

08:03 ET Webcast Alert: Barr Laboratories, Inc. Announces Fourth Quarter/Fiscal 2002 Year End Webcast

  
Aug 02, 02

17:32 ET Barr Labs Announces Fourth Quarter/Fiscal 2002 Year End Earnings Release Date and Conference Call

  
Jun 28, 02

09:49 ET Barr Launches Two Additional Generic Oral Contraceptive Products

  
Jun 21, 02

13:36 ET Barr's Cenestin(R) 0.3 Mg Tablets Approved Broadens Cenestin Product Franchise to Four Strengths

  
Jun 12, 02

13:05 ET Barr Receives Approval for Lithium Carbonate Extended-Release Tablets 300 mg

  
Jun 06, 02

10:53 ET Barr Completes Asset Purchase of Enhance Pharmaceuticals

  
Jun 03, 02

08:27 ET Barr Elects Governor James S. Gilmore, III, to Board of Directors

  
May 24, 02

09:10 ET Barr's Generic Nordette(R) Tablets Approved

  
May 22, 02

09:10 ET Barr Says Arington Resigns from Board of Directors; Former Duramed Chief to Pursue Other Business Ventures

  
May 08, 02

08:04 ET Barr Third Quarter 2002 EPS Climbs to $1.17; Revenues Increase 64% to $261.4 Million in Quarter

  
08:00 ET Webcast Alert: Barr Laboratories, Inc. Announces Its Third Quarter Fiscal 2002 Earnings Conference Call on the Web; Live and Archived Conference Call Notification

  
May 07, 02

11:08 ET Barr Challenging Patents Protecting Remeron(R) SolTab(TM)

  
May 06, 02

10:00 ET Barr's SEASONALE(TM) Oral Contraceptive Phase III Clinical Trial Results Subject of ACOG Poster Session

  
May 03, 02

09:15 ET Barr Terms Shire's Adderall Trade Dress Infringement Suit Without Merit; Calls Court Action Last Attempt to Sabotage Consumer Savings

  
May 02, 02

08:00 ET Webcast Alert: Barr Laboratories, Inc. Announces Its Third Quarter Fiscal 2002 Earnings Conference Call on the Web; Live and Archived Conference Call Notification

  
Apr 30, 02

09:54 ET Barr, Bristol-Myers Restructure Former DuPont Product Development And Marketing Agreements

  
Apr 29, 02

09:25 ET Barr Labs Announces Third Quarter Fiscal 2002 Earnings Release Date and Conference Call

  
Apr 24, 02

13:04 ET Barr's Generic Fosamax(R) 70 mg Tablet and 35 mg Tablet Products Tentatively Approved by FDA

  
Apr 23, 02

11:28 ET Barr Launches Lessina(TM) Oral Contraceptive Tablets; Generic Levlite(TM) Tablets Marketed as Branded Generic

  
Apr 08, 02

08:37 ET Barr Receives Final Approval for Generic Mircette(R) Oral Contraceptive Company Will Launch Product Immediately Under Kariva(TM) Trademark

  
Mar 21, 02

16:00 ET Barr Signs Asset Purchase Agreement with Enhance Pharmaceuticals, Inc.; $44 million Cash Purchase Would Give Company Novel Vaginal Drug Delivery Technology, Several NDA Products in Various Stages of Development

  
08:05 ET Barr's Generic Levlite(TM) Tablets Approved

  
Mar 06, 02

10:44 ET Barr Signs Agreements With Natural Biologics, LLC to Develop 'AB' Rated Conjugated Estrogens

  
Mar 05, 02

09:33 ET Barr Challenging Patents Protecting Niaspan(R) 1000 mg Extended-Release Tablet

  
Feb 28, 02

10:47 ET Barr Names Frederick J. Killion Senior Vice President & General Counsel Brings 20 Years of Experience to General Counsel Position

  
Feb 11, 02

15:46 ET Barr Receives Approval for Generic Adderall(R) Tablets

  
Feb 04, 02

09:04 ET Barr Receives Approval for Generic Prozac(R) 10 mg Tablets Company Will Launch Immediately

  
Jan 31, 02

15:17 ET Barr Receives Approval for Generic Prozac(R) 10 mg Capsules; Company Will Launch Immediately

  
Jan 30, 02

10:49 ET Barr Challenging Patents Protecting ALLEGRA-D(R); Company Also Challenging Allegra Capsule and Tablet Patents

  
Jan 29, 02

07:36 ET Barr Reports Second Quarter 2002 EPS of $0.91 Excluding Merger Related Charges and Other Non-Recurring Items EPS Was $1.40